Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk A/S

https://www.novonordisk.com/

Latest From Novo Nordisk A/S

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Sales & Earnings Renal

Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says

Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.

Metabolic Disorders Reimbursement

Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion

The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.

Scrip Asks Diversity & Inclusion
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Carbometrics
    • Corvidia Therapeutics
    • Neose Technologies, Inc.
    • Novo Holdings A/S
    • Novo Nordisk Pharmaceuticals, Inc.
    • Pharmaero Aps
    • Xellia Pharmaceuticals ApS
    • Ziylo Ltd
UsernamePublicRestriction

Register